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Introduction
 Head and neck cancer squamous cell carcinoma 
(HNSCC) is a term given to epithelial malignancies that 
arise in the oral cavity, paranasal sinuses, nasal cavity, 
pharynx, and larynx (Argiris et al., 2008; Rudolph et 
al., 2011). Almost 90% of HNSCC originating from the 
mucosal lining of these regions (Dobrossy, 2005). HNSCC 
is strongly associated with certain environmental and 
lifestyle risk factors including tobacco smoking and high 
alcohol consumption (Dobrossy, 2005). The successful 
treatment of these patients depends on early detection and 
appropriate therapy (Rezende et al., 2010). The incomplete 
resection of primary tumour frequently leads to decrease 
in the survival rate as a consequence of increased risk of 
recurrence; therefore, complete surgical resection of the 
tumour is a crucial prognostic step for HNSCC (Armstrong 
et al., 2010; Jalali et al., 2011). 
 Molecular markers can be used to establish tumour 
free surgical margins and assist in complete resection of 
1School of Psychological and Clinical Sciences, Charles Darwin University, 2Alan Walker Cancer Care Centre, 3Anatomical Pathology, 
4Department of Head and Neck Surgery, Royal Darwin Hospital, Darwin, Northern Territory, Australia  *For correspondence: 
Rama.Jayaraj@cdu.edu.au
Abstract
 Complete surgical resection of the primary tumour is a crucial predictive step for head and neck squamous 
cell carcinoma (HNSCC), because incomplete resection may lead to increase in the recurrence rate. Molecular 
cancer markers have been investigated as potential predictors of prognosis marker, to identify patients who are 
at high risk of local recurrence. This retrospective study aimed to determine the prognostic correlation between 
p53 and eIF4E expression and clinical characteristics, recurrence and overall survival. Forty eight HNSCC 
patients were selected between 2006 and 2009 diagnosed at the Royal Darwin Hospital, Darwin, Northern 
Territory, Australia. Out of 48, only those 24 with negative surgical margins with hematoxylin and eosin (HandE) 
were chosedn for further analysis. A total of 77 surgical margins were obtained and subsequently analysed by 
immunohistochemical (IHC) staining with monoclonal p53 and polyclonal eIF4E antibodies. Contingency table 
and χ2-test were used to investigate the correlation between p53 and eIF4E expression and clinical characteristics, 
recurrence and overall survival of the HNSCC patients. The follow up period was 74 months (range 1-74 months). 
The Kaplan-Meier method was used to generate recurrence and survival curves. This is a first retrospective 
study of Northern Territory patients, including Indigenous and non-Indigenous Australians. Molecular study of 
surgical margins could help to identify patients with and without clear margins after surgery and help in choice 
of the most appropriate adjuvant treatment for HNSCC patients.  
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the tumour (Nathan et al., 1999). To establish the reliable 
molecular cancer markers, the marker should be specific 
for tumour cells that could differentiate normal and 
tumour cells (Roncella et al., 2005). Potential biomarkers 
have greatly expanded our understanding of molecular 
pathways involved in tumour initiation and tumour 
progression (Pai and Westra, 2009). The ability to detect 
malignancy at the molecular level with appropriate tumour 
markers could help to prevent the high local recurrence 
rate by allowing for a more precise determination of cancer 
involvement at the surgical margins. This would also help 
in predicting recurrence and possibly lead to adjunctive 
therapies for patients at higher risk for recurrence (Nathan 
et al., 1997). Molecular examination of surgical margins 
could be batter therapeutic method over histopathology 
to identify patients with high risk of local recurrence and 
tumour related deaths.
 The p53 is one the most frequently studied molecular 
markers in HNSCC (Van Houten et al., 2002; Waitzberg 
et al., 2004; Poeta et al., 2007; Jalali et al., 2011). It is 
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the p53 that plays a significant role in pathways that are 
responsible for maintaining cellular integrity (Bradford 
et al., 2013). The p53 network is activated when cells 
are damaged or stressed. In the activation form, the p53 
protein can lead to cell cycle arrest and DNA repair, 
or it can cause programmed cell death (van Oijen and 
Slootweg, 2000). Alteration in p53 protein function may 
result from either mutation in its gene or sequestration 
by the other cellular protein (Gasco and Crook, 2003). 
Mutations of p53 gene are one of the common genetic 
abnormalities in many cancers including HNSCC 
(Hardisson, 2003; Jalali et al., 2011). The mutation of 
p53 genes leads to the pathogenesis of HNSCC patients 
with expression range of p53 protein from 50 to 60% of 
the tumour cells (Nathan et al., 2000; Bradford et al., 
2013). The significant function of p53 expression has 
been widely analysed by IHC methods to identify the 
number of cancers, including breast cancer. However, the 
role of p53 protein in HNSCC is incompletely understood 
(Song et al., 2006). IHC analysis of p53 network may be 
diagnostic and prognostic use in the clinical management 
of HNSCC (Gasco and Crook, 2003). 
 Eukaryotic translation factor 4E (eIF4E) is protein 
involved in the initiation of protein synthesis (Chen et 
al., 2004). However, overexpression of eIF4E not only 
induces the transformation and tumorgenesis, but also 
initiates metastasis (De Benedetti and Graff, 2004). 
Overexpression of eIF4E is sufficient to develop the 
transformation of fibroblasts and primary epithelial 
cells (Avdulov et al., 2004). In a clinical trial, eIF4E 
overexpression indicates to increase cancer susceptibility 
because eIF4E transgenic mice develop lymphomas, 
angiosarcomas, lung carcinomas, and hepatomas (Ruggero 
et al., 2004). Previous studies have been observed 100% 
expression of eIF4E in HNSCC (Cardesa and Nadal, 2011; 
Nathan et al., 1997). One study has reported that eIF4E 
overexpression found in cancer tissue than the normal 
mucosa by using IHC (Rosenwald et al., 2001).
Association between p53 and eIF4E expression and 
clinical outcomes
 A previous study suggests that IHC staining with 
p53 has an advantage over histopathology to identify the 
patients at high risk for local recurrence (Van Houten 
et al., 2004). This finding indicate some limitations of 
histological diagnosis and the potential for molecular 
markers to guide clinicians in the management of 
HNSCC (Nathan et al., 2000). It has been highlighted 
that the overexpression of p53 is often associated with 
clinicopathological findings of the tumour, lymph node 
metastases, and survival of HNSCC patients (Waitzberg 
et al., 2004). 
 The 5-year survival rate for HNSCC remains low after 
diagnosis, that is approximately 50% (Jemal et al., 2008; 
Kokko et al., 2011). Significantly, five year survival rate 
in HNSCC is lower than other cancers, such as those of 
colorectal, cervix, and breast origin, due to detection of 
advanced stage disease (Jemal et al., 2008; Clark et al., 
2010). With advent of new surgical procedures, improved 
radiotherapy and concomitant chemotherapy, there is 
a considerable improvement in local recurrence (Van 
Houten et al., 2004). However, the survival rates for 
HNSCC have not significantly improved (Partridge et al., 
2007; Argiris et al., 2008). It is generally believed that 
incomplete resection of the primary tumour is the principal 
reason of death from HNSCC type of cancer (Armstrong 
et al., 2010). A previous study of p53 observed that the 
survival rate was higher with p53 negative patients than 
p53 positive (Jalali et al., 2011).
 In retrospective studies of breast, bladder, and HNSCC, 
the overexpression of eIF4E protein was correlated 
with an increased risk of disease progression and poor 
prognosis (Crew et al., 2000; De Benedetti and Graff, 
2004; Liangping, 2005). Elevated level of eIF4E in tumour 
free surgical margins was correlated with local regional 
recurrence in patients with HNSCC (Chakraborty et al., 
2008). A previous study on lung cancer indicated that the 
patients with high eIF4E expression showed poor survival 
after surgery than patients with low eIF4E expression 
(Wang et al., 2009). The study of breast cancer patients 
observed that the patients with high expression of eIF4E 
had significantly higher rate of recurrence and cancer 
related death (Holm et al., 2008). The above studies on 
lung and breast cancer found that the expression of eIF4E 
can be considered as an independent prognostic predictor 
for recurrence and survival.
Hypothesis
 The p53 and eIF4E have been used to detect the sub-
optical tumours including HNSCC. Clinical pathologists 
use light microscopy to investigate correlation between 
recurrent/residual cancer and overexpression of these 
molecular markers in optically negative margins of 
HNSCC resection. The absence of p53 and eIF4E 
overexpression may benefit the patient in terms of 
avoiding unnecessary treatment, decrease local recurrence 
and increase survival. This will also help decrease the 
incidence of residual disease, perhaps downstage the need 
for radiation therapy, and certainly aid in the reduction of 
disease-specific mortality in head and neck cancers.
Objectives 
 i) To determine the correlation between p53 and eIF4E 
expression in the surgical margin and clinical outcomes; 
ii) To determine the correlation between expression of p53 
and eIF4E in positive surgical tumour margins and clinical 
characteristics; iii) To investigate whether eIF4E is a more 
sensitive molecular marker than p53 in surgical margins 
to predict successful outcomes from surgical treatment, 
and prevention of recurrence of cancer.
Materials and Methods
Design of study
 This retrospective study was performed on the paraffin 
embedded tissue sections of patients who underwent 
primary surgical resection for HNSCC. Primarily, we have 
selected 48 HNSCC patients between 2006 and 2009. 
They were diagnosed at the Royal Darwin Hospital. The 
study design is illustrated in Figure 1. Paraffin embedded 
samples from histologically tumour free surgical margins 
of HNSCC patients were examined. The expressions of 
p53 and eIF4E protein were evaluated with IHC method 
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by using p53 and eIF4E antibodies. 
 The patient’s clinical characteristics including 
demographic and pathological characteristics were 
collected for this study (Table 1). Then, relationship 
between expression of p53 and eIF4E and clinical 
characteristics were analysed (Figure 2). The primary 
endpoint is local recurrence and secondary endpoint is 
overall survival of 24 HNSCC patients.
Patients selection and eligibility criteria
Target population and level of involvement 
 There was no patient involvement in the project. 
Tissue samples from the patients diagnosed and treated for 
mucosal oro-pharyngeal HNSCC (excluding superficially 
excised skin malignancies) from March 2005 to December 
2009 at Royal Darwin Hospital.
Inclusion criteria
 Out of 48, 24 patients were included in our study with 
histologically tumour free surgical margins. Experienced 
pathologists were examined the surgical margins of 48 
HNSCC patients.
Exclusion criteria
 The remaining twenty four patients were excluded 
because they had histologically positive surgical margins.
Follow-up
 The follow up period for 24 HNSCC patients was 74 
months (range 1-74 months). We have reviewed the effect 
of recurrence with p53 and eIF4E expression in the 24 
HNSCC patients. Out of 24 patients, 7 patients had local 
recurrence and 12 patients died during the follow-up 
period.
Immunohistochemical staining 
 All slides with tissue section were labelled with an 
appropriate bar code before the IHC staining procedure. 
These labelled slides were placed horizontally by metal 
clip on the level carousal in the temperature-equilibrated 
chamber of Ventana Benchmark XT machine (Ventana Pty 
Ltd). The Ventana Benchmark XT machine commenced 
processing the tissue samples upon loading of the 
programmed p53 and eIF4E IHC procedure file. Each 
procedure file consisted of a specific sequence of buffer 
rinse, enzyme inhibitors, blocking serum, antibody 
detection complexes, chromogens, and counter-stains, 
which were used according to the manufacturer’s 
instructions. 
 After a series of buffer rinses and normal serum pre-
incubation, antibodies (monoclonal mouse p53 antibody 
(Dako Pty Ltd, Australia) at 1:200 and polyclonal eIF4E 
(Abcam Pty Ltd, USA) antibody at 1:500 dilutions) were 
dispensed using 100µl metered dose per slide. The slides 
were treated with streptavidin-enzymes conjugated and a 
brown staining with diaminobenzidine (DAB) (Dako Pty 
Ltd, Australia) with copper sulphate enhancement. Each 
staining step was incubated for exact time and at 420C 
standard temperature. After the incubation, the instruments 
in each section were rinsed to halt the reaction and remove 
Table 1. Patient’s Clinical Characteristics
Clinical characteristics  Category
Age ≥ 50
 ≤ 50 
Sex Male
 Female
Race Indigenous 
 non-Indigenous
Anatomical sites Floor of mouth
 Tongue
 Lips
 Tonsil
Tumour stage* T1
 T2
 T3
 T4
Nodal status Positive
 Negative
Nodal stage** N0
 N1
 N2b
Post-op XRT*** No
 Yes
Histological grade Poorly differentiated 
 Moderate differentiated 
 Well differentiated 
*Tumour stage I (T1)=Tumour 2 cm or less, Tumour stage II (T2)=Tumour larger 
than 2 cm but not larger than 4 cm, Tumour stage III (T3)=Tumour larger than 4 
cm, Tumour stage IV (T4)=Tumour with extension to bone, muscle, skin, antrum, 
neck, **Nodal stage 0 (N0)=No regional lymph node involvement, Nodal stage 
1 (N1)=involvement of regional lymph node smaller than 3 cm, Nodal stage 2b 
(N2b)=involvement of multiple regional lymph nodes smaller than 6 cm, ***Post-op 
XRT=post operative irradiation therapy
Figure 1. The Study Schema of the p53 and eIF4E 
Molecular Study
48 HNSCC patients 
selected at Royal 
Darwin Hospital
H&E examination
p53 examination
48 HNSCC patients 
with negative surgical 
margins
48 HNSCC patients 
with positive surgical 
margins
eIF4E IHC 
examination Excluded
Follow-up period 
up to 74 months
7 patients had 
local recurrence 12 patients died
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the unbounded material that could cause unnecessary 
background staining. 
 At the end of automated staining process, the slides 
were washed in hot water with detergent for 3 minutes to 
remove the oily material. Then slides were dehydrated 
through the series of ethanol dilutions and then followed 
by treatment in xylene. Finally, the cover slips were placed 
on each slide and fixed with permanent mounting material.
Microscopic examination of p53 and eIF4E expression 
 All the IHC stained slides were evaluated for the 
expression of p53 and eIF4E protein by light microscopy 
‘in blinded manner’ by two pathologists who were 
unaware of the clinical details. The stained slides of 
tumour margins were evaluated for p53 and eIF4E protein 
expression. The 5% cut-off value was selected on the 
basis of p53 and eIF4E expression in tumour cells in the 
basal cell layer of surgical margin (Nathan et al., 2000). 
Therefore, surgical margins were considered as a positive 
if IHC staining observed in >5% of the cells in epithelial 
layer. 
 These tumour margins were graded as positive with 
p53 if there is brown nuclear staining in the basal cell 
layer of epithelium. Similarly, surgical margins were 
considered as positive with eIF4E if there is reddish brown 
peri-nuclear cytoplasmic staining of >5% in the layer of 
epithelium.
Results 
 The clinical characteristics of 24 HNSCC patients and 
surgical margins were examined statistically with SPSS 
software (SPSS Version 19) for this research. Time to 
recurrence was considered as the period from surgery to 
the date of the first documented recurrence (Nathan et al., 
2000). Local recurrence was defined as a recurrence in 
the original tumour bed (Chao et al., 2012). The overall 
survival time was defined as the interval between the dates 
of the beginning of the treatment (surgery) and the death or 
the last information for censored observations (Waitzberg 
et al., 2004). 
 The records of 24 HNSCC patient’s status were 
obtained from the Royal Darwin Hospital and the 
Department of Births, Deaths and Marriages, Darwin, 
Australia. Those records were reviewed for patient’s 
survival. In our study, we have compared the effect of 
survival rate with the expression of p53 and eIF4E in the 
surgical margins.
 Contingency Tables and χ2-test were used to evaluate 
the association of p53 and eIF4E in the surgical margins 
with age, sex, race, anatomical sites, tumour stage, nodal 
status, nodal stage, post-operative therapy and histological 
grade. Univariate analysis was performed to identify 
significant involvement of the above variables with cancer 
prognosis. Event time distribution for recurrence and 
survival rate were estimated by the Kaplan-Meier method 
and compared by the log-rank test (Nathan et al., 2000; 
Song et al., 2006). 
Outcomes and significance 
 The translation of the proposed research study in the 
clinical setting will have a direct impact on Australian 
Indigenous community health and health services in 
the Northern Territory. While the target population of 
our research study primarily comprises of Australian 
Indigenous patients, the outcomes of this project will 
impact on cancer care for all such patients in the Northern 
Territory.
 The use of molecular markers to identify the clear 
surgical margins may decrease local recurrence of 
HNSCC. Determining the correlation between biomarkers 
and clinical outcomes will allow for better patient care 
planning in the future. 
 The use of these p53 and eIF4E detection may become 
routine practice protocols in our clinical pathology setting, 
dictated by the study findings.
Clinical implications of this study
 If our null hypothesis concerning immunohistochemical 
(p53 or eIF4E) margins being positive in a setting 
where routine histology reports a tumour free margin is 
confirmed, the clinical implications in the clinical setting 
will be: i) Routine usage of p53 and eIF4E in the primary 
assessment of surgical margins for all HNSCC tumours 
resected; ii) Additional therapy, either as more resection 
and/or radiation therapy to ensure that the primary ablation 
is complete; iii) Improved outcomes, with reduced 
recurrence and/or residual disease and potential metastatic 
disease; increased disease free survival after treatment for 
HNSCC in the Northern Territory; iv) Reduced overall 
costs to the patient, family, community and health services.
Discussion
This study will significantly contribute to the field 
of head and neck oncology. It will also help to improve 
the service delivery for surgeon and raise awareness 
of the incidence of HNSCC in the Northern Territory 
population. Findings from this study will highlight the 
rate of complications in the management of head and neck 
oncology in the Northern Territory and this will allow 
comparison with other centres.
Molecular study of the surgical margin could help 
to identify patients with and without clear margins after 
surgery. It also helps to choose the appropriate adjuvant 
treatment for HNSCC patients. The role of p53 and eIF4E 
marker expression in the future management of HNSCC is 
significant. It appears logical and feasible that rapid testing 
Figure 2. The Relationship between Expression of p53 
and eIF4E and Clinical Outcomes
Analysis of 
correlation
Expression 
of p53 marker
Expression 
of eIF4E marker
Clinical Outcomes
Local recurrence
Overall survival
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will inform the surgical team if their resection is adequate, 
and permit further guide excision at directed margins.
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